Evolocumab 140 mg or alirocumab 150 mg every two weeks are the most effective PCSK9 inhibitor doses for lowering Lp(a), a network meta-analysis of 41 trials (J Cardiovasc Pharmacol 2023)

Original title: Effect of Different Types and Dosages of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-analysis

J Cardiovasc Pharmacol · 1 June 2023 · 7

Yu Z, Hu L, Sun C, Wang Z, Zhang X, Wu M, Liu L

This network meta-analysis pooled 41 randomised controlled trials (17,601 participants, 23 distinct interventions) comparing PCSK9 inhibitors, alirocumab, evolocumab and inclisiran, on Lp(a) levels, though Lp(a) was a secondary rather than primary endpoint in all included trials. Most PCSK9 inhibitors significantly reduced Lp(a) versus placebo, by up to 25.1%, with no significant difference between most agents. Alirocumab 150 mg every 2 weeks outperformed alirocumab at 150, 200 or 300 mg every 4 weeks, and evolocumab 140 mg every 2 weeks outperformed alirocumab 150 mg every 4 weeks, with evolocumab 140 mg every 2 weeks ranking as the most effective regimen overall. The authors conclude that a biweekly dose of either agent is the preferred option, though a single PCSK9 inhibitor alone may not provide sufficient clinical benefit for patients with very high residual Lp(a)-related risk.

Original abstract

Lipoprotein(a) [Lp(a)] has become an important component of the residual risk of cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors display promising effects in controlling Lp(a) levels. However, the effects of different types and dosages of PCSK9 inhibitors on Lp(a) have not been studied in detail. These include 2 monoclonal antibodies, alirocumab and evolocumab, and inclisiran, a small interfering RNA. We searched PubMed, Web of Science, Embase, and Cochrane Library for randomized controlled trials to investigate the efficacy of PCSK9 inhibitors at the Lp(a) level. Although changes in Lp(a) levels were not the primary endpoint in any of these studies, they all described these valuable data. Forty-one randomized controlled trials with 17,601 participants were included, involving 23 unduplicated interventions. Most PCSK9 inhibitors significantly reduced Lp(a) levels compared with placebo. The pairwise comparison demonstrated no significant difference among most PCSK9 inhibitors. However, in the comparison among different dosages of alirocumab, the dosage of 150 mg Q2W showed a significant reduction in Lp(a) levels compared with the dosages of 150, 200, and 300 mg Q4W. In addition, the comparison results demonstrated the significant efficacy of evolocumab 140 mg Q2W compared with alirocumab at a dosage of 150 mg Q4W. The cumulative rank probabilities demonstrated that evolocumab 140 mg Q2W showed the highest efficacy. This study showed that PCSK9 inhibitors reduced Lp(a) levels by up to 25.1%. A biweekly dose of either 140 mg evolocumab or 150 mg alirocumab was the best treatment option. However, the reduction in Lp(a) levels with a single kind of PCSK9 inhibitor alone did not demonstrate sufficient clinical benefit. Therefore, for patients with very high Lp(a) levels who remain at high residual risk in the context of statin administration, it may be acceptable to use a kind of PCSK9 inhibitor, but the clinical benefit needs further investigation.

Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.